Clinical trials: Drug-Induced Liver Injury, open to volunteers
Drug Induced Liver Injury
Drug-Induced Liver Injury (DILI) Network Retrospective
The purpose of this study is to establish retrospectively a nationwide registry of patients who have suffered drug-induced liver injury (DILI), and to collect, immortalize, and store serum, DNA, and lymphocytes from these…
- Trial name
- ILIAD (NCT00360646)
- Where
- 6 sites in United States
- Volunteers
- 400 people
- Sponsor
- Duke University
Drug-induced Liver Injury
A Prospective Cohort Study on Drug-induced Liver Injury in China（DILI-P）
This is a multi-center, prospective, non-interventional cohort study . Its primary objectives are: 1. assess DILI patients' clinical characteristics, disease progression and influencing factors in clinical practice; 2.
- Trial name
- DILI-P (NCT02961413)
- Where
- China
- Volunteers
- 10,000 people
- Sponsor
- Drug Induced Liver Disease Study Group
Acetaminophen, Drug-Induced Liver Injury
Screening of Susceptibility Genes for APAP Induced Drug Induced LIver Injury in ChiNese Population: a Case-control Study
Acetaminophen (APAP) is the most commonly used NSAIDS in clinic, and it is also a common cause of drug-induced liver injury (DILI).
- Conditions
- Acetaminophen, Drug-Induced Liver Injury, Pharmacogenetics, China
- Trial name
- PAIN (NCT04964310)
- Testing
- genetic polymorphism
- Where
- China
- Volunteers
- 339 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University